Cite
HARVARD Citation
Nakagawa, K. et al. (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 20 (12), pp. 1655-1669. [Online].